China Lung Cancer Screening Market by Product Type, Application, and End-Use: Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

Persistence Market Research has recently released a comprehensive report on the China lung cancer screening market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the China lung cancer screening market from 2025 to 2032.

Key Insights:

Projected Market Value (2032F): USD 1,295.5 Million

China Market Growth Rate (CAGR 2025 to 2032): 11.2%

China Lung Cancer Screening Market Size (2025E): USD 616.2 Million

Lung Cancer Screening Market - Report Scope:

Lung cancer screening plays a vital role in the early detection of lung cancer, significantly improving survival rates by identifying malignancies at a treatable stage. Screening methods, including low-dose computed tomography (LDCT), have become widely adopted in healthcare facilities across China, driven by a surge in lung cancer incidence linked to smoking, air pollution, and occupational hazards. The lung cancer screening market in China serves hospitals, diagnostic imaging centers, cancer care facilities, and community health programs, with a focus on early detection, personalized risk assessments, and integration with AI-powered diagnostic tools. Market expansion is supported by rising awareness campaigns, government-led screening programs, and technological advancements enhancing diagnostic accuracy and screening efficiency.

Market Growth Drivers:

The China lung cancer screening market is propelled by increasing government initiatives promoting early cancer detection, particularly under the Healthy China 2030 initiative. The rising prevalence of lung cancer, especially in urban and industrialized regions, underscores the urgent need for effective screening programs. Technological advancements, such as AI-assisted image analysis and improved LDCT systems, offer better accuracy in nodule detection and classification, boosting clinician confidence and patient outcomes. Additionally, the expansion of public health insurance coverage for lung cancer screening and improved healthcare access in rural areas contribute to market growth. Collaborations between public health institutions and private diagnostics firms also facilitate the implementation of large-scale screening programs targeting high-risk populations.

Market Restraints:

Despite a strong growth outlook, the lung cancer screening market in China faces several challenges. Limited access to advanced imaging technology in underdeveloped regions restricts screening coverage. High costs associated with LDCT systems and ongoing maintenance, along with a shortage of skilled radiologists, hamper market penetration. Concerns regarding false positives and radiation exposure from repeated screenings may also deter individuals from participating in screening programs. Regulatory complexities and regional disparities in screening protocols pose additional hurdles. Addressing these issues requires policy reforms, investment in infrastructure, and enhanced training programs for medical personnel to ensure consistent and accurate screening practices nationwide.

Market Opportunities:

Significant growth opportunities exist in the development of AI-integrated screening tools, mobile screening units, and risk-based stratification models tailored to China’s diverse population demographics. The growing adoption of digital health platforms enables tele-radiology services and remote diagnostic support, increasing screening accessibility in remote and underserved areas. Investment in public-private partnerships and cross-border collaborations can accelerate the introduction of innovative screening technologies and expand service networks. Moreover, raising public awareness through education campaigns and promoting annual screenings for high-risk individuals create additional avenues for growth in the Chinese market.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the lung cancer screening market in China?

Which screening technologies and protocols are gaining traction across different healthcare settings?

How are advancements in AI and imaging reshaping lung cancer screening in China?

Who are the key players contributing to the China lung cancer screening market, and what strategies are they employing to maintain competitiveness?

What are the emerging trends and future prospects in China’s lung cancer screening ecosystem?

Competitive Intelligence and Business Strategy:

These companies are investing in AI-powered CT systems, mobile screening units, and cloud-based diagnostics to enhance early detection capabilities. Partnerships with public health institutions and hospitals support broader deployment and training programs. Furthermore, companies are exploring opportunities for value-based care models and outcome-driven screening programs to align with national health goals.

Key Companies Profiled:

Biodesix

GE HealthCare

DELFI Diagnostics, Inc.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

CANON MEDICAL SYSTEMS CORPORATION

Siemens Healthineers AG

Medtronic plc

Koninklijke Philips N.V.

Freenome Holdings, Inc.

Shanghai United Imaging Healthcare Co., LTD.

Others

China Lung Cancer Screening Market Research Segmentation:

The lung cancer screening market in China encompasses a range of technologies, risk groups, end-user institutions, and regional dynamics, addressing early detection and risk mitigation strategies.

By Cancer Type

Non-small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

By Diagnosis

Low Dose Spiral CT Scan

Chest X-ray

By End-use

Hospitals and Clinics

Diagnostic Centers

Others

By Province

Anhui

Guizhou

Guangdong

Shandong

Jiangsu

Others